Insights+: Key Deals of JP Morgan Healthcare Conference 2021
Shots: The last patient is out from the P-IIb part of its multinational P-IIb/III study of NP-120 for the COVID-19 has now completed treatment with 2wk follow up The company reports positive interim results for the P-IIb part of it P-IIb/III Ifenprodil COVID-19 study and expecting the final data set by end of Feb 2021 […]Read More